| Gene symbol | RHO | Synonyms | CSNBAD1, OPN2, RP4 | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3q22.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | rhodopsin | ||||
| GTO ID | GTC3398 |
| Trial ID | NCT05805007 |
| Disease | Retinitis Pigmentosa |
| Altered gene | RHO |
| Therapeutic/Target gene | Target gene |
| Therapy | Gene editing |
| Treatment | ZVS203e |
| Phase | Early_Phase1 |
| Recruitment status | Recruiting |
| Title | A Single-arm, Open-label Exploratory Clinical Study to Assess the Preliminary Safety of the Gene Editing Drug ZVS203e for the Management of Retinitis Pigmentosa Caused by Mutations in the RHO Gene |
| Year | 2023 |
| Country | China |
| Company sponsor | Peking University Third Hospital |
| Other ID(s) | ZYB-2022-001 |
| Vector information | |||||||
|
|||||||
| Cohort 1 | |||||||
|
|||||||